---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-24-000085"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:21:08.552099+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurogene Q2 net loss $18.5M; NGN-401 gets RMAT and START FDA designations

## Summary
- Cash and equivalents $153.9M as of June 30, 2024; expected to fund operations into 2H 2026.
- Net loss $18.5M in Q2 2024 vs $11.9M in Q2 2023; R&D expenses rose to $15.7M from $10.3M.
- NGN-401 for Rett syndrome received RMAT designation and was selected for FDA START Pilot Program.
- First patient dosed in high-dose Cohort 2; interim efficacy data from Cohort 1 expected Q4 2024.
- Enrollment complete in NGN-101 for CLN5 Batten disease; data and regulatory update in Q1 2025.

## SEC filing metadata
- accession: 0001404644-24-000085
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000085/0001404644-24-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000085/ngne-20240809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-24-000085
- JSON: https://secwatch.observer/filing/0001404644-24-000085.json
- Plain text: https://secwatch.observer/filing/0001404644-24-000085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.